Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression

Yu Chan Chang, Yung Chieh Chan, Wei Ming Chang, Yuan Feng Lin, Chih Jen Yang, Chia Yi Su, Ming Shyan Huang, Alexander T.H. Wu, Michael Hsiao

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Distant metastasis and recurrence are the greatest challenges in the clinical management of lung cancer. Despite advances in targeted therapies, high mortality rates persist. Therefore, alternative therapeutic interventions are urgently required. Accumulating evidence indicates that normalizing tumor metabolism may be a way to increase therapeutic efficacy and to reduce tumor malignancy. Here, we analyzed integrated transcriptomics data and an shRNA library against glycolytic enzymes and found that elevated Aldolase A expression is highly correlated with metastatic potential and a poor prognosis in patients with non-small cell lung cancer (NSCLC). We validated our in silico findings with an immunohistochemical analysis of clinical samples. Aldolase A silencing significantly suppressed metastatic potential both in vitro and in vivo, whereas the ectopic overexpression of Aldolase A resulted in the opposite phenotype. Furthermore, our microarray and Ingenuity Pathway Analyses (IPA) revealed that Aldolase A-driven lung cancer metastasis was closely linked to hypoxia inducible factor 1 alpha (HIF-1α)-downstream signaling. Importantly, Aldolase A overexpression may promote the release of lactate to block PHD activities and further induce HIF-1α stabilization. Aldolase A and nuclear HIF-1α overexpression levels were positively correlated and were significantly associated with a poorer survival rate in lung cancer patients (P = 0.008 for Overall Survival, P = 0.021 for Disease-free Survival). Furthermore, MMP9, a downstream target of HIF-1α, was significantly upregulated after ALDOA overexpression. A MMP9 inhibitor significantly inhibited cell invasion and migration in ALDOA-HIF-1α axis-induced lung cancer. In summary, our results reveal the molecular mechanism of Aldolase A in promoting lung cancer metastasis via PHD-mediated stabilization of HIF-1α and the subsequent activation of MMP9. The ALDOA-HIF-1α axis may provide a new therapeutic target for metastatic lung cancer treatment.

Original languageEnglish
Pages (from-to)28-36
Number of pages9
JournalCancer Letters
Volume403
DOIs
Publication statusPublished - Sep 10 2017

Fingerprint

Hypoxia-Inducible Factor 1
Fructose-Bisphosphate Aldolase
Lung Neoplasms
Neoplasm Metastasis
Therapeutics
Neoplasms
Non-Small Cell Lung Carcinoma
Computer Simulation
Small Interfering RNA
Disease-Free Survival
Cell Movement
Lactic Acid
Survival Rate
Phenotype
Recurrence
Survival
Mortality
Enzymes

Keywords

  • Aldolase A
  • HIF-1α stabilization
  • Lung cancer metastasis
  • MMP9
  • Proline-hydroxylase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression. / Chang, Yu Chan; Chan, Yung Chieh; Chang, Wei Ming; Lin, Yuan Feng; Yang, Chih Jen; Su, Chia Yi; Huang, Ming Shyan; Wu, Alexander T.H.; Hsiao, Michael.

In: Cancer Letters, Vol. 403, 10.09.2017, p. 28-36.

Research output: Contribution to journalArticle

Chang, Yu Chan ; Chan, Yung Chieh ; Chang, Wei Ming ; Lin, Yuan Feng ; Yang, Chih Jen ; Su, Chia Yi ; Huang, Ming Shyan ; Wu, Alexander T.H. ; Hsiao, Michael. / Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression. In: Cancer Letters. 2017 ; Vol. 403. pp. 28-36.
@article{d4e539e3ceb747c58ec579e8f0988491,
title = "Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression",
abstract = "Distant metastasis and recurrence are the greatest challenges in the clinical management of lung cancer. Despite advances in targeted therapies, high mortality rates persist. Therefore, alternative therapeutic interventions are urgently required. Accumulating evidence indicates that normalizing tumor metabolism may be a way to increase therapeutic efficacy and to reduce tumor malignancy. Here, we analyzed integrated transcriptomics data and an shRNA library against glycolytic enzymes and found that elevated Aldolase A expression is highly correlated with metastatic potential and a poor prognosis in patients with non-small cell lung cancer (NSCLC). We validated our in silico findings with an immunohistochemical analysis of clinical samples. Aldolase A silencing significantly suppressed metastatic potential both in vitro and in vivo, whereas the ectopic overexpression of Aldolase A resulted in the opposite phenotype. Furthermore, our microarray and Ingenuity Pathway Analyses (IPA) revealed that Aldolase A-driven lung cancer metastasis was closely linked to hypoxia inducible factor 1 alpha (HIF-1α)-downstream signaling. Importantly, Aldolase A overexpression may promote the release of lactate to block PHD activities and further induce HIF-1α stabilization. Aldolase A and nuclear HIF-1α overexpression levels were positively correlated and were significantly associated with a poorer survival rate in lung cancer patients (P = 0.008 for Overall Survival, P = 0.021 for Disease-free Survival). Furthermore, MMP9, a downstream target of HIF-1α, was significantly upregulated after ALDOA overexpression. A MMP9 inhibitor significantly inhibited cell invasion and migration in ALDOA-HIF-1α axis-induced lung cancer. In summary, our results reveal the molecular mechanism of Aldolase A in promoting lung cancer metastasis via PHD-mediated stabilization of HIF-1α and the subsequent activation of MMP9. The ALDOA-HIF-1α axis may provide a new therapeutic target for metastatic lung cancer treatment.",
keywords = "Aldolase A, HIF-1α stabilization, Lung cancer metastasis, MMP9, Proline-hydroxylase",
author = "Chang, {Yu Chan} and Chan, {Yung Chieh} and Chang, {Wei Ming} and Lin, {Yuan Feng} and Yang, {Chih Jen} and Su, {Chia Yi} and Huang, {Ming Shyan} and Wu, {Alexander T.H.} and Michael Hsiao",
year = "2017",
month = "9",
day = "10",
doi = "10.1016/j.canlet.2017.06.001",
language = "English",
volume = "403",
pages = "28--36",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression

AU - Chang, Yu Chan

AU - Chan, Yung Chieh

AU - Chang, Wei Ming

AU - Lin, Yuan Feng

AU - Yang, Chih Jen

AU - Su, Chia Yi

AU - Huang, Ming Shyan

AU - Wu, Alexander T.H.

AU - Hsiao, Michael

PY - 2017/9/10

Y1 - 2017/9/10

N2 - Distant metastasis and recurrence are the greatest challenges in the clinical management of lung cancer. Despite advances in targeted therapies, high mortality rates persist. Therefore, alternative therapeutic interventions are urgently required. Accumulating evidence indicates that normalizing tumor metabolism may be a way to increase therapeutic efficacy and to reduce tumor malignancy. Here, we analyzed integrated transcriptomics data and an shRNA library against glycolytic enzymes and found that elevated Aldolase A expression is highly correlated with metastatic potential and a poor prognosis in patients with non-small cell lung cancer (NSCLC). We validated our in silico findings with an immunohistochemical analysis of clinical samples. Aldolase A silencing significantly suppressed metastatic potential both in vitro and in vivo, whereas the ectopic overexpression of Aldolase A resulted in the opposite phenotype. Furthermore, our microarray and Ingenuity Pathway Analyses (IPA) revealed that Aldolase A-driven lung cancer metastasis was closely linked to hypoxia inducible factor 1 alpha (HIF-1α)-downstream signaling. Importantly, Aldolase A overexpression may promote the release of lactate to block PHD activities and further induce HIF-1α stabilization. Aldolase A and nuclear HIF-1α overexpression levels were positively correlated and were significantly associated with a poorer survival rate in lung cancer patients (P = 0.008 for Overall Survival, P = 0.021 for Disease-free Survival). Furthermore, MMP9, a downstream target of HIF-1α, was significantly upregulated after ALDOA overexpression. A MMP9 inhibitor significantly inhibited cell invasion and migration in ALDOA-HIF-1α axis-induced lung cancer. In summary, our results reveal the molecular mechanism of Aldolase A in promoting lung cancer metastasis via PHD-mediated stabilization of HIF-1α and the subsequent activation of MMP9. The ALDOA-HIF-1α axis may provide a new therapeutic target for metastatic lung cancer treatment.

AB - Distant metastasis and recurrence are the greatest challenges in the clinical management of lung cancer. Despite advances in targeted therapies, high mortality rates persist. Therefore, alternative therapeutic interventions are urgently required. Accumulating evidence indicates that normalizing tumor metabolism may be a way to increase therapeutic efficacy and to reduce tumor malignancy. Here, we analyzed integrated transcriptomics data and an shRNA library against glycolytic enzymes and found that elevated Aldolase A expression is highly correlated with metastatic potential and a poor prognosis in patients with non-small cell lung cancer (NSCLC). We validated our in silico findings with an immunohistochemical analysis of clinical samples. Aldolase A silencing significantly suppressed metastatic potential both in vitro and in vivo, whereas the ectopic overexpression of Aldolase A resulted in the opposite phenotype. Furthermore, our microarray and Ingenuity Pathway Analyses (IPA) revealed that Aldolase A-driven lung cancer metastasis was closely linked to hypoxia inducible factor 1 alpha (HIF-1α)-downstream signaling. Importantly, Aldolase A overexpression may promote the release of lactate to block PHD activities and further induce HIF-1α stabilization. Aldolase A and nuclear HIF-1α overexpression levels were positively correlated and were significantly associated with a poorer survival rate in lung cancer patients (P = 0.008 for Overall Survival, P = 0.021 for Disease-free Survival). Furthermore, MMP9, a downstream target of HIF-1α, was significantly upregulated after ALDOA overexpression. A MMP9 inhibitor significantly inhibited cell invasion and migration in ALDOA-HIF-1α axis-induced lung cancer. In summary, our results reveal the molecular mechanism of Aldolase A in promoting lung cancer metastasis via PHD-mediated stabilization of HIF-1α and the subsequent activation of MMP9. The ALDOA-HIF-1α axis may provide a new therapeutic target for metastatic lung cancer treatment.

KW - Aldolase A

KW - HIF-1α stabilization

KW - Lung cancer metastasis

KW - MMP9

KW - Proline-hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=85021142984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021142984&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.06.001

DO - 10.1016/j.canlet.2017.06.001

M3 - Article

C2 - 28610954

AN - SCOPUS:85021142984

VL - 403

SP - 28

EP - 36

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -